Parnassus Investments
Parnassus Endeavor Fund
Parnassus Endeavor Fund AstraZeneca PLC stake
total: 118
Parnassus Endeavor Fund AZN trades
- Total transactions:
- 2
- New positions:
- 1
- Reduced:
- 1
- Held since:
- 2026 Q1
- Held for:
- 2 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Parnassus Endeavor Fund holds 620,569 AstraZeneca PLC (AZN) shares with a market value of roughly $117.67M accounting for 2.23% of the overall portfolio. To date, the estimated cost basis is nearly $197.22 for "buy" trades and estimated average "sell" price is $189.62. Parnassus Endeavor Fund first purchased AZN in 2026 Q1, initially acquiring 634,492 shares. Since the initial investment in AstraZeneca PLC (AZN), Parnassus Endeavor Fund has made 1 more transaction.
When did Parnassus Endeavor Fund buy AstraZeneca PLC (AZN)?
Parnassus Endeavor Fund first invested in AstraZeneca PLC (AZN) in 2026 Q1 at the reported quarter-end price of $197.22 per share.
What's the cost basis of Parnassus Endeavor Fund's AZN stake?
The estimated cost basis for AstraZeneca PLC (AZN) stake is around $197.22 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $197.22
- Weighted AVG sell price:
- $189.62
Parnassus Endeavor Fund's historical trades in AstraZeneca PLC
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
2.23%
|
620,569
|
$189.62
|
$117,672,294
|
-2.19% (-13,923)
|
-0.06%
|
|
2026 Q1
|
2.71%
|
634,492
|
$197.22
|
$125,134,512
|
new
|
+2.71%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.